Dyadic & Scripps Research Partner on Hantavirus Antibodies & Vaccines
Dyadic International announced a collaboration between Dyadic Applied BioSolutions and Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including the Andes virus. This partnership aims to leverage Dyadic's proprietary C1 platform to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing for public health events. The C1 platform has demonstrated comparable efficacy to traditional mammalian systems in preclinical studies and is already involved in other funded collaborations with organizations like the Gates Foundation and CEPI. Dyadic also continues to focus on commercial opportunities in non-pharmaceutical protein products.
Key Highlights
- Dyadic and Scripps Research collaborate on hantavirus monoclonal antibody and vaccine candidates.
- The partnership focuses on Andes virus, linked to Hantavirus Pulmonary Syndrome (HPS).
- Utilizes Dyadic's C1 platform for rapid development and large-scale biologic manufacturing.
- C1 platform previously demonstrated GMP-compliant manufacturing and Phase 1 clinical evaluation.
- Ongoing collaborations include support from Gates Foundation, CEPI, and Fondazione Biotecnopolo di Siena.
- C1-produced antibodies showed comparable binding and neutralization to mammalian systems.
- Dyadic and Scripps plan to jointly explore external partnership and non-dilutive funding.
- Dyadic also highlights growing commercial activity in non-pharmaceutical applications.
Price Impact
More from DYAI